EICHORPublic-registry site landscape for NCT04040049, “A Fabry Disease Gene Therapy Study”, a Fabry Disease study sponsored by Spur Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04040049 (registry record) |
| Study title | A Fabry Disease Gene Therapy Study |
| Official title | A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry Disease |
| Sponsor | Spur Therapeutics |
| Condition(s) | Fabry Disease; Lysosomal Storage Diseases |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 13 |
| Site countries | United States, Austria, Canada, Germany, Italy, Norway, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT04040049.
Eichor generates a preliminary site-risk snapshot for NCT04040049 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Spur Therapeutics
← Eichor home · All tracked trials · Fabry Disease studies · Weekly briefs
